NL-OMON43099已完成3 期
Optimisation of [68Ga] PSMA-11 PET/CT Imaging Protocol for localizing primary prostate cancer prior to radical prostatectomy - Optimisation of [68]Ga-PSMA PET/CT protocol
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •* Male aged 18 years or older
- •* Ability to provide signed informed consent and willingness to comply with protocol requirements.
- •* Biopsy confirmed presence of adenocarcinoma of the prostate gland
- •* Planned/already executed mpMRI (standard of care).
- •* Planned for radical prostatectomy (standard of care).
排除标准
- •* Have any medical condition or other circumstances that, in the opinion of the investigator, would significantly decrease obtaining reliable data, achieving study objectives, or completing the study. (part A and B)
- •* Have a contraindication for mpMRI. (part A and B)
- •* Will not undergo a radical prostatectomy. (part A and B)
- •* Claustrophobia (part A and B)
- •* Multiple malignancies (part A and B)
- •* Anticoagulant therapy (part A)
- •* Obese (>120 kg) (part A)
- •* Have undergone a transurethral resection of prostate in the past (part A and B)
研究者
相似试验
进行中（未招募）
1 期
Optimisation of [68Ga] PSMA-11 PET/CT Imaging Protocol for finding the location of prostate cancer lesions in patients who were newly diagnosed with prostate cancerPrimary localised prostate cancer, in men who opt for active treatment in the form of a radical prostatectomyEUCTR2016-002485-31-NLniversity Medical Center Groningen
进行中（未招募）
1 期
Investigation of 68GaPSMA PET/CT as an imaging biomarker in solid tumorsadvanced/metastatic solid tumorsMedDRA version: 20.0Level: LLTClassification code 10027477Term: Metastatic carcinomaSystem Organ Class: 100000004864EUCTR2016-004376-21-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS400
尚未招募
不适用
Optimisation of [68Ga] PSMA-11 PET/CT Imaging Protocol for localizing primary prostate cancer prior to radical prostatectomyNL-OMON29500niversiy Medical center Groningen (UMCG)20
进行中（未招募）
1 期
Prospective evaluation of 68Ga-PSMA PET-CT for Recurrence detection of Prostate Cancer and its impact on patient management. The ProsPERo TrialMales 18 years of age or older with histologically-proven prostate adenocarcinoma and biochemical relapse with rising PSA level after initial treatment with radical curative intent, not yet on palliative systemic treatment and considered for further salvage therapyMedDRA version: 19.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10068979Term: Imaging procedureSystem Organ Class: 10022891 - InvestigationsEUCTR2016-000842-79-BEInstitut Jules Bordet75
招募中
不适用
Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1Prostate CancerNCT06353321University of Texas Southwestern Medical Center25